Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accumulated Expenses (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Accumulated Expenses for 7 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 34.73% to $40.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.9 million through Dec 2025, up 34.73% year-over-year, with the annual reading at $40.9 million for FY2025, 34.73% up from the prior year.
  • Accumulated Expenses hit $40.9 million in Q4 2025 for IDEAYA Biosciences, down from $45.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $45.3 million in Q3 2025 to a low of $2.7 million in Q2 2021.
  • Historically, Accumulated Expenses has averaged $17.3 million across 5 years, with a median of $15.4 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: plummeted 73.12% in 2023 and later soared 508.96% in 2025.
  • Year by year, Accumulated Expenses stood at $4.0 million in 2021, then skyrocketed by 328.08% to $17.0 million in 2022, then tumbled by 58.97% to $7.0 million in 2023, then soared by 335.22% to $30.4 million in 2024, then soared by 34.73% to $40.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for IDYA at $40.9 million in Q4 2025, $45.3 million in Q3 2025, and $37.8 million in Q2 2025.